Research
Novel Sjogren's Drug Passes First Phase III Test
The Brief
- Dazodalibep, an investigational CD40L antagonist, was tested in a 48-week phase III trial for Sjögren's disease.
- Results reported at the ORLANDO meeting suggest the drug is nearing the finish line on the way to approval, according to MedPage Today.
Why it matters
A positive phase III result is a key step toward a new treatment option for Sjögren's disease, a condition with few approved disease-modifying drugs.
Who’s affected
- patients with Sjögren's disease
- rheumatologists and clinicians who treat autoimmune disease
- #sjogren's
- #clinical trials
- #autoimmune disease
- #drug development
- #dazodalibep
(MedPage Today) -- ORLANDO -- An investigational CD40L antagonist called dazodalibep looks to be nearing the finish line on the way to approval for Sjögren's disease, based on results from a 48-week phase III trial reported here. With scores...
Timeline
48-week phase III results for dazodalibep reported at the ORLANDO meeting
MedPageToday.com - medical news for physicians
Novel Sjogren's Drug Passes First Phase III Test